Personalis, Inc. (PSNL)

Personalis, Inc.'s stock (PSNL) has experienced significant volatility with a 52-week range between $2.83 and $11.50. Recent price changes include a drop of 5.53% on February 6, 2026, but the stock price has increased by 79.50% over the last 12 months. Key events impacting the stock include a downward revision of 2025 revenue guidance due to a decline in pharmaceutical services revenue and logistical challenges, insider selling of approximately $1,131,353.00 in company stock, a 41% quarter-over-quarter increase in NeXT Personal Dx volumes for Q4 2025, and the acquisition of Medicare coverage for the NeXT Personal MRD test.

There is no clear or distinct demand seasonality reported for Personalis, Inc.'s products and services. The demand for its advanced cancer genomic tests and services appears to be driven more by ongoing research, clinical trials, and the evolving landscape of personalized cancer therapies rather than specific seasonal cycles.

Personalis, Inc. is a precision oncology company focused on transforming cancer management through advanced genomic testing and analytics. The company operates within the Healthcare sector, specifically in the Diagnostics & Research industry, and develops and markets advanced cancer genomic tests and analytics, supporting the development of personalized cancer vaccines and next-generation cancer immunotherapies. Its major products and platforms include NeXT Personal, ImmunoID NeXT, NeXT Personal Dx, NeXT Dx, Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS), NeXT Platform, NeXT Liquid Biopsy, NeXT SHERPA and NeXT NEOPS, and ACE platform.

Personalis, Inc. is headquartered in Fremont, California, and conducts its operations in the United States and internationally. The company's revenue has primarily been generated in the United States, with a smaller portion from other regions in past fiscal periods.

Personalis, Inc. has maintained a generally positive brand reputation, driven by its innovative contributions to personalized cancer medicine and strategic collaborations. The company has received a consensus rating of "Moderate Buy" or "Strong Buy" from analysts, with an average target price suggesting significant upside potential. Key factors contributing to its reputation include strategic collaborations with Tempus AI, Inc. and Moderna, recognition for innovation in cancer genomics, and clinical success demonstrated by the increase in clinical test volumes for NeXT Personal Dx.

The ownership structure of Personalis (PSNL) stock is a mix of institutional, retail, and individual investors. Approximately 25.12% of the company's stock is owned by Institutional Investors, 0.68% by Insiders, and 74.20% by Public Companies and Individual Investors. Another source indicates that 61.91% of the stock is held by institutions and 3.80% by insiders. Major institutional owners include Merck & Co., Inc., Lightspeed Management Company, L.L.C., ARK Investment Management LLC, ARKG - ARK Genomic Revolution ETF, BlackRock, Inc., AIGH Capital Management LLC, Vanguard Group Inc, Standard Life Aberdeen plc, T. Rowe Price Investment Management, Inc., and Kennedy Capital Management, Inc.